189 related articles for article (PubMed ID: 36110930)
61. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
[TBL] [Abstract][Full Text] [Related]
62. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
[TBL] [Abstract][Full Text] [Related]
63. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration.
Winship A; Van Sinderen M; Heffernan-Marks A; Dimitriadis E
Int J Oncol; 2017 Mar; 50(3):798-804. PubMed ID: 28098860
[TBL] [Abstract][Full Text] [Related]
64.
Man F; Koers A; Karagiannis P; Josephs DH; Bax HJ; Gilbert AE; Dodev TS; Mele S; Chiarruttini G; Crescioli S; Chauhan J; Blower JE; Cooper MS; Spicer J; Karagiannis SN; Blower PJ
Oncoimmunology; 2021; 10(1):1966970. PubMed ID: 34513315
[TBL] [Abstract][Full Text] [Related]
65. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
66. A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.
Tarone L; Giacobino D; Camerino M; Maniscalco L; Iussich S; Parisi L; Giovannini G; Dentini A; Bolli E; Quaglino E; Merighi IF; Morello E; Buracco P; Riccardo F; Cavallo F
Mol Ther; 2023 Aug; 31(8):2342-2359. PubMed ID: 37312451
[TBL] [Abstract][Full Text] [Related]
67. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.
Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA
PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730
[TBL] [Abstract][Full Text] [Related]
68. Isolating subpopulations of human epidermal basal cells based on polyclonal serum against trypsin-resistant CSPG4 epitopes.
Gunnarsson AP; Christensen R; Praetorius J; Jensen UB
Exp Cell Res; 2017 Jan; 350(2):368-379. PubMed ID: 28011196
[TBL] [Abstract][Full Text] [Related]
69. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
70. Chondroitin sulfate proteoglycan 4 regulates zebrafish body axis organization via Wnt/planar cell polarity pathway.
Lee YH; Kawakami K; HuangFu WC; Liu IH
PLoS One; 2020; 15(4):e0230943. PubMed ID: 32240230
[TBL] [Abstract][Full Text] [Related]
71. CSPG4 as a prognostic biomarker in chordoma.
Schoenfeld AJ; Wang X; Wang Y; Hornicek FJ; Nielsen GP; Duan Z; Ferrone S; Schwab JH
Spine J; 2016 Jun; 16(6):722-7. PubMed ID: 26689475
[TBL] [Abstract][Full Text] [Related]
72. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
[TBL] [Abstract][Full Text] [Related]
73. The chrondroitin sulfate proteoglycan (CSPG4) regulates human trophoblast function.
Van Sinderen M; Cuman C; Winship A; Menkhorst E; Dimitriadis E
Placenta; 2013 Oct; 34(10):907-12. PubMed ID: 23953863
[TBL] [Abstract][Full Text] [Related]
74. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
75. Receptor Binding Domains of TcdB from
Henkel D; Tatge H; Schöttelndreier D; Tao L; Dong M; Gerhard R
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255261
[TBL] [Abstract][Full Text] [Related]
76. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
[TBL] [Abstract][Full Text] [Related]
77. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
78. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
79. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM; Schroeder S; Knopf P; Krahl AC; Hau J; Schleicher S; Martella M; Quintanilla-Martinez L; Kneilling M; Pichler B; Lang P; Atar D; Schilbach K; Handgretinger R; Schlegel P
Oncoimmunology; 2020; 9(1):1683345. PubMed ID: 32002293
[TBL] [Abstract][Full Text] [Related]
80. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
